Figure 1From: Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase geneMedian tumor weight in mg in nude Swiss female mice xenografted with RL-7 or RL-G cells and treated with gemcitabine (200 mg/Kg i.p. once a week; 6 doses) or untreated. RL-7 control: mice injected with RL-7 cells, untreated; RL-7 Gem: mice injected with RL-7 cells, treated with gemcitabine; RL-G control: mice injected with RL-G cells, untreated; RL-G Gem: mice injected with RL-G cells, treated with gemcitabine.Back to article page